Page last updated: 2024-08-24

triazoles and oxyntomodulin

triazoles has been researched along with oxyntomodulin in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (12.50)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	6 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adrian, TE; Bilchik, AJ; Modlin, IM; Nilsson, O; Sussman, J; Zucker, KA	1
Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S	1
Berry, D; Berry, S; Chien, J; Gaydos, B; Geiger, MJ; Skrivanek, Z	1
Bakris, GL; Flynn, C	1
Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS	1
Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G	1
Thompson, AM; Trujillo, JM	1
Hussar, DA	1

Reviews

5 review(s) available for triazoles and oxyntomodulin

Article	Year
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current opinion in clinical nutrition and metabolic care, 2008, Volume: 11, Issue:4 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nature reviews. Nephrology, 2013, Volume: 9, Issue:3 Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2013
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgraduate medicine, 2014, Volume: 126, Issue:6 Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2014
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3 Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms	2015
New drugs 2015, part 3. Nursing, 2015, Volume: 45, Issue:10 Topics: Acids, Carbocyclic; Benzoxazines; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cephalosporins; Cyclopentanes; Drug Approval; Drug Combinations; Drug Therapy; Glucagon-Like Peptides; Guanidines; Humans; Imidazoles; Immunoglobulin Fc Fragments; Interferon-beta; Isoquinolines; Penicillanic Acid; Polyethylene Glycols; Pyridines; Quinuclidines; Recombinant Fusion Proteins; Tazobactam; Triazoles; United States; United States Food and Drug Administration	2015

Trials

2 trial(s) available for triazoles and oxyntomodulin

Article	Year
An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. Journal of diabetes science and technology, 2012, Nov-01, Volume: 6, Issue:6 Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Research Design; Sitagliptin Phosphate; Triazoles	2012
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes care, 2014, Volume: 37, Issue:8 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2014

Article

Year

An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics.

Journal of diabetes science and technology, 2012, Nov-01, Volume: 6, Issue:6

Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Research Design; Sitagliptin Phosphate; Triazoles

2012

Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Diabetes care, 2014, Volume: 37, Issue:8

Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles

2014

Other Studies

1 other study(ies) available for triazoles and oxyntomodulin

Article	Year
H2-receptor blockade induces peptide YY and enteroglucagon-secreting gastric carcinoids in mastomys. Surgery, 1989, Volume: 106, Issue:6 Topics: Animals; Carcinogens; Carcinoid Tumor; Gastric Mucosa; Gastrointestinal Hormones; Glucagon-Like Peptides; Histamine H1 Antagonists; Hyperplasia; Muridae; Peptide YY; Peptides; Reference Values; Stomach; Stomach Neoplasms; Triazoles	1989